Michael A Morrissey

US Patent:

20030003479, Jan 2, 2003

Filed:

Apr 19, 2002

Appl. No.:

10/126227

Inventors:

Steven Kovats - Wilmington MA, US
Ami Sen - Framingham MA, US
Michael Morrissey - Brighton MA, US
James Lillie - Natick MA, US

Assignee:

Millennium Pharmaceutical, Inc. - Cambridge MA

International Classification:

C12Q001/68
C07H021/04

US Classification:

435/006000, 536/023200

Abstract:

The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers. A variety of marker genes are provided, wherein changes in the levels of expression of one or more of the marker genes is correlated with the presence of ovarian cancer.

US Patent:

20030148314, Aug 7, 2003

Filed:

Aug 1, 2002

Appl. No.:

10/210314

Inventors:

Allison Berger - Watertown MA, US
Tracy Guillemette - Waltham MA, US
Barbara Bryant - Cambridge MA, US
Michael Morrissey - Brighton MA, US
Robert Schlegel - Auburndale MA, US

Assignee:

MILLENNIUM PHARMACEUTICALS, INC. - Cambridge MA

International Classification:

C12Q001/68
G01N033/574
C07H021/04
C12N009/00
C12P021/02
C12N005/06

US Classification:

435/006000, 435/007230, 435/069300, 435/183000, 435/320100, 435/325000, 530/388260, 536/023200

Abstract:

The invention relates to newly discovered nucleic acid molecules and proteins associated with colon cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human colon cancers are provided.

US Patent:

20040156854, Aug 12, 2004

Filed:

Dec 4, 2003

Appl. No.:

10/728055

Inventors:

George Mulligan - Lexington MA, US
Barbara Bryant - Cambridge MA, US
Michael Morrissey - Brighton MA, US
Andrew Bolt - Somerville MA, US
Andrew Damokosh - West Hartford CT, US

Assignee:

Millennium Pharmaceuticals, Inc.

International Classification:

C12Q001/68
G01N033/574
A61K039/395

US Classification:

424/155100, 435/006000

Abstract:

The present invention is directed to the identification of markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with responsiveness or non-responsiveness to a therapeutic regimen comprising proteasome inhibition. Thus, by examining the expression levels of individual markers and those comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.

US Patent:

20050214831, Sep 29, 2005

Filed:

Feb 4, 2005

Appl. No.:

11/050926

Inventors:

John Monahan - Walpole MA, US
Manjula Gannavarapu - Acton MA, US
Sebastian Hoersch - Arlington MA, US
Shubhangi Kamatkar - Newton MA, US
Steven Kovats - Wilmington MA, US
Rachel Meyers - Newton MA, US
Michael Morrissey - Brighton MA, US
Peter Olandt - Watertown MA, US
Ami Sen - Framingham MA, US
Petter Veiby - Westborough MA, US
Gordon Mills - Houston TX, US
Robert Bast - Houston TX, US
Karen Lu - Houston TX, US
Rosemarie Schmandt - Houston TX, US
Xumei Zhao - Wayland MA, US
Karen Glatt - Natik MA, US

Assignee:

MILLENNIUM PHARMACEUTICALS, INC. - Cambridge MA

International Classification:

C12Q001/68
G01N033/574

US Classification:

435006000, 435007230

Abstract:

The invention relates to newly discovered nucleic acid molecules and proteins associated with ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers are provided.

US Patent:

20090181393, Jul 16, 2009

Filed:

Dec 16, 2008

Appl. No.:

12/316756

Inventors:

George Mulligan - Lexington MA, US
Barbara M. Bryant - Cambridge MA, US
Michael P. Morrissey - Brighton MA, US
Andrew Bolt - Somerville MA, US
Andrew I. Damokosh - West Hartford CT, US

International Classification:

C12Q 1/68
G01N 33/574

US Classification:

435 6, 435 723

Abstract:

The present invention is directed to the identification of markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with responsiveness or non-responsiveness to a therapeutic regimen comprising proteasome inhibition. Thus, by examining the expression levels of individual markers and those comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.

US Patent:

20110183962, Jul 28, 2011

Filed:

Sep 28, 2009

Appl. No.:

13/119072

Inventors:

Marion Dorsch - Jamaica Plain MA, US
John E. Monahan - Walpole MA, US
Michael Patrick Morrissey - Watertown MA, US
Shifeng Pan - San Diego CA, US
Juliet Williams - London, GB

Assignee:

Novartis AG - Basel

International Classification:

A61K 31/553
A61K 31/5377
A61K 31/501
A61K 31/4184
A61K 31/4745
A61K 31/496
A61K 31/44
A61K 31/505
A61K 31/47
A61K 31/506
A61K 31/444
A61P 35/00

US Classification:

51421108, 5142355, 51425202, 514394, 514293, 51425303, 5142358, 514277, 514275, 514311, 514256, 514333

Abstract:

The invention provides methods for modulating, e.g., antagonizing, the activity of the Hedgehog signaling pathway, and for treating Hedgehog related disorders such as cancers (e.g., medulloblastoma). In particular, the invention provides methods for inhibiting aberrant growth states resulting from phenotypes such as Ptch loss-of-function, Hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function by administering to a mammal combinations of Smoothened inhibitors (e.g., a compound of Formula I, Formula II, or Formula III, or any of the compounds listed herein or incorporated by reference) and cholesterol biosynthesis pathway inhibitors (e.g., statins), Gli inhibitors, and/or Phosphatidylinositol 3-kinase (PI3K) inhibitors.

US Patent:

20140056912, Feb 27, 2014

Filed:

Apr 27, 2012

Appl. No.:

14/114418

Inventors:

Seth Alexander Ettenberg - Melrose MA, US
Vivien W. Chan - Emeryville CA, US
Michael Patrick Morrissey - Watertown MA, US
David Jenkins - Carlisle MA, US

Assignee:

Novartis AG - Basel

International Classification:

A61K 39/395

US Classification:

4241581

Abstract:

The disclosure relates to methods for treating a sclerostin-expressing cancer, e.g., a squamous cell carcinoma (SCC), e.g., SCC of the upper aerodigestive tract, esophagus, or lung, employing a therapeutically effective amount of at least one sclerostin antagonist, e.g., an anti-sclerostin antibody, such as Antibody 1, 2, 3, 4 or 5.

US Patent:

20170023577, Jan 26, 2017

Filed:

Mar 25, 2016

Appl. No.:

15/080709

Inventors:

- Cambridge MA, US
Barbara M. Bryant - Cambridge MA, US
Michael P. Morrissey - Brighton MA, US
Andrew Bolt - Somerville MA, US
Andrew I. Damokosh - West Hartford CT, US

International Classification:

G01N 33/574
A61K 38/05
C12Q 1/68

Abstract:

The present invention is directed to the identification of markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with responsiveness or non-responsiveness to a therapeutic regimen comprising proteasome inhibition. Thus, by examining the expression levels of individual markers and those comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.